Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial

Vivek Shinde, Iksung Cho, Joyce S. Plested, Sapeckshita Agrawal, Jamie Fiske, Rongman Cai, Haixia Zhou, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Bin Zhou, Maggie Lewis, Patty Price-Abbott, Nita Patel, Michael J Massare, Gale Smith, Cheryl Keech, Louis Fries, Gregory M Glenn
doi: https://doi.org/10.1101/2020.08.07.20170514
Vivek Shinde
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vshinde@novavax.com
Iksung Cho
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S. Plested
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sapeckshita Agrawal
2Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with Assembly Biosciences, 331 Oyster Point Blvd, South San Francisco, CA 94080
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Fiske
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongman Cai
3Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with Parexel, 1 Federal St, Billerica, MA 01821
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haixia Zhou
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuan Pham
4Previously with Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878. Currently with AstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, MD 20878.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Wang
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Zhou
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maggie Lewis
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Price-Abbott
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J Massare
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Keech
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Fries
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M Glenn
1Novavax Inc., 21 Firstfield Road, Gaithersburg, MD 20878
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Improved seasonal influenza vaccines for older adults are urgently needed, which can induce broadly cross-reactive antibodies and enhanced T-cell responses, particularly against A(H3N2) viruses, while avoiding egg-adaptive antigenic changes.

Methods We randomized 2654 clinically-stable, community-dwelling adults ≥65 years of age 1:1 to receive a single intramuscular dose of either Matrix-M-adjuvanted quadrivalent nanoparticle influenza vaccine (qNIV) or a licensed inactivated influenza vaccine (IIV4) in this randomized, observer-blinded, active-comparator controlled trial conducted during the 2019-2020 influenza season. The primary objectives were to demonstrate the non-inferior immunogenicity of qNIV relative to IIV4 against 4 vaccine-homologous strains, based on Day 28 hemagglutination-inhibiting (HAI) antibody responses, described as geometric mean titers and seroconversion rate difference between treatment groups, and to describe the safety of qNIV. Cell-mediated immune (CMI) responses were measured by intracellular cytokine analysis.

Findings qNIV demonstrated immunologic non-inferiority to IIV4 against 4 vaccine-homologous strains as assessed by egg-based HAI antibody responses. Corresponding wild-type HAI antibody responses by qNIV were significantly higher than IIV4 against all 4 vaccine-homologous strains (22-66% increased) and against 6 heterologous A(H3N2) strains (34-46% increased), representing multiple genetically and/or antigenically distinct clades/subclades (all p-values <0.001). qNIV induced 3.·1- to 3·9- and 4·0- to 4·9-fold increases in various polyfunctional phenotypes of antigen-specific effector CD4+ T-cells against A(H3N2) and B/Victoria strains at Day 7 post-vaccination, respectively, while corresponding fold-rises induced by IIV4 at Day 7 were 1·3-1·4 and 1·7-2·0; representing a 126-189% improvement in CMI responses for qNIV (all p-values <0·001). Local reactogenicity, primarily mild to moderate and transient pain, was higher in the qNIV group.

Interpretation qNIV was well tolerated and produced a qualitatively and quantitatively enhanced humoral and cellular immune response in older adults. These enhancements may be critical to improving the effectiveness of currently licensed influenza vaccines.

Funding Novavax.

Competing Interest Statement

All co-authors are or were employees of Novavax, Inc. at the time of the study

Clinical Trial

NCT04120194

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04120194

Funding Statement

Funding was provided by Novavax, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the Advarra Institutional Review Board (Columbia, Maryland, USA).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • vshinde{at}novavax.com

  • icho{at}novavax.com

  • jplested{at}novavax.com

  • sapeck.srivastava{at}gmail.com

  • jfiske{at}novavax.com

  • rongmancai.m{at}gmail.com

  • hzhou{at}novavax.com

  • xuanami9{at}gmail.com

  • mzhu{at}novavax.com

  • wcloneyclark{at}novavax.com

  • wongnan{at}hotmail.com

  • bzhou{at}novavax.com

  • mlewis{at}novavax.com

  • pprice-abbott{at}novavax.com

  • npatel{at}novavax.com

  • mmassare{at}novavax.com

  • gsmith{at}novavax.com

  • ckeech{at}novavax.com

  • lfries{at}Novavax.com

  • gglenn{at}novavax.com

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available as analyses are ongoing and will be used for regulatory submissions for the vaccine described; but may become available in the future from the corresponding author on reasonable request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 11, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial
Vivek Shinde, Iksung Cho, Joyce S. Plested, Sapeckshita Agrawal, Jamie Fiske, Rongman Cai, Haixia Zhou, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Bin Zhou, Maggie Lewis, Patty Price-Abbott, Nita Patel, Michael J Massare, Gale Smith, Cheryl Keech, Louis Fries, Gregory M Glenn
medRxiv 2020.08.07.20170514; doi: https://doi.org/10.1101/2020.08.07.20170514
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial
Vivek Shinde, Iksung Cho, Joyce S. Plested, Sapeckshita Agrawal, Jamie Fiske, Rongman Cai, Haixia Zhou, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Bin Zhou, Maggie Lewis, Patty Price-Abbott, Nita Patel, Michael J Massare, Gale Smith, Cheryl Keech, Louis Fries, Gregory M Glenn
medRxiv 2020.08.07.20170514; doi: https://doi.org/10.1101/2020.08.07.20170514

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (196)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5681)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (866)
  • Geriatric Medicine (88)
  • Health Economics (231)
  • Health Informatics (762)
  • Health Policy (390)
  • Health Systems and Quality Improvement (252)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6474)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (92)
  • Neurology (847)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (260)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (106)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (966)
  • Public and Global Health (2228)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)